natgillin/translations-raw huggingface dataset:
After oral administration of 14C-labelled rasagiline, elimination occurred primarily via urine (62.6%) and secondarily via faeces (21.8%), with a total recovery of 84.4% of the dose over a period of 38 days. 
Nakon peroralne primjene 14C-označenog razagilina, eliminacija se primarno odvija urinom (62,6 %), a sekundarno putem fecesa (21,8 %), s potpunim izlučivanjem 84,4 % doze lijeka tijekom razdoblja od 38 dana.
Patients with Parkinson's disease are particularly vulnerable to the adverse reactions of hypotension due to existing gait issues. 
Bolesnici s Parkinsonovom bolesti posebno su osjetljivi na nuspojave hipotenzije zbog postojećih problema s hodanjem.
Patients should be cautioned about operating hazardous machines, including motor vehicles, until they are reasonably certain that rasagiline does not affect them adversely. 
Bolesnici trebaju biti oprezni pri upravljanju opasnim strojevima, uključujući motorna vozila, dok nisu dovoljno sigurni da razagilin na njih ne utječe štetno.
Skin melanoma* 
Melanom kože*
Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with rasagiline. 
Bolesnike treba obavijestiti o tome i savjetovati ih da budu oprezni dok upravljaju vozilima ili rade sa strojevima tijekom terapije razagilinom.
Aluminium/aluminium blister packs of 7, 10, 28, 30, 100 or 112 tablets. 
Aluminij/aluminij blister pakiranja od 7, 10, 28, 30, 100 ili 112 tableta.
Food does not affect the Tmax of rasagiline, although Cmax and exposure (AUC) are decreased by approximately 60% and 20%, respectively, when the medicinal product is taken with a high fat meal. 
Hrana ne utječe na Tmax razagilina, iako je Cmax smanjen za približno 60 %, a izloženost (AUC) za približno 20 % kada se lijek uzima s obrokom s visokim udjelom masnoća.
The recommended dose of rasagiline is 1 mg (one tablet of Rasagiline ratiopharm) once daily, to be taken with or without levodopa. 
Preporučena doza razagilina je 1 mg (jedna tableta lijeka Razagilin ratiopharm) jednom dnevno koja se uzima s levodopom ili bez nje.
Rasagiline pharmacokinetics is linear with dose over the range of 0.5-2 mg in Parkinson's disease patients. 
Farmakokinetika razagilina je linearna s dozama u rasponu od 0,5-2 mg u bolesnika s Parkinsonovom bolešću.
In post-marketing experience, these symptoms have also been observed in Parkinson's disease patients treated with rasagiline. 
U iskustvu nakon stavljanja lijeka u promet, ovi su simptomi opaženi i u bolesnika s Parkinsonovom bolešću liječenih razagilinom.
Do not use this medicine after the expiry date which is stated on the carton, bottle or blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji, bočici ili blisteru iza oznake „EXP“ ili „Rok valjanosti“.
Excessive daily sleepiness (hypersomnia, lethargy, sedation, sleep attacks, somnolence, sudden onset of sleep) can occur in patients treated with dopamine agonists and/or other dopaminergic treatments. 
Prekomjerna dnevna pospanost (hipersomnija, letargija, sedacija, napadaji sna, somnolencija, iznenadni nastup sna) mogu se javiti kod bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim lijekovima.
Injury, poisoning and procedural complications 
Ozljede, trovanja i procedu ralne komplik acije
Results of five tyramine challenge studies (in volunteers and Parkinson's disease patients), together with results of home monitoring of blood pressure after meals (of 464 patients treated with 0.5 or 1 mg/day of rasagiline or placebo as adjunct therapy to levodopa for six months without tyramine restrictions), and the fact that there were no reports of tyramine/rasagiline interaction in clinical studies conducted without tyramine restriction, indicate that rasagiline can be used safely without dietary tyramine restrictions. 
Rezultati iz pet ispitivanja izloženosti tiraminu (u dobrovoljaca i bolesnika s Parkinsonovom bolešću), zajedno s rezultatima kućnog nadziranja krvnog tlaka nakon obroka (464 bolesnika liječenih s 0,5 ili 1 mg/dan razagilina ili placebom kao dodatnom terapijom levodopi kroz šest mjeseci bez restrikcija tiramina) i činjenicom da nije bilo prijava tiramin/razagilin interakcija u kliničkim ispitivanjima provedenim bez restrikcije tiramina, upućuju na to da se razagilin može primijenjivati sigurno bez dijetalnih restrikcija tiramina.
Rasagiline's pharmacokinetics characteristics in subjects with mild (CLcr 50-80 ml/min) and moderate (CLcr 30-49 ml/min) renal impairment were similar to healthy subjects. 
Karakteristike farmakokinetike razagilina u osoba s blagim (CLcr 50-80 ml/min) i umjerenim (CLcr 30-49 ml/min) oštećenjem bubrega su slične onima zdravih osoba.
Rasagiline was not carcinogenic in rats at systemic exposure, 84 - 339 times the expected plasma exposures in humans at 1 mg/day. 
Razagilin nije bio kancerogen u štakora pri sistemskoj ekspoziciji 84-339 puta većoj od očekivane plazmatske ekspozicije u ljudi pri dozi od 1 mg/dan.
Since rasagiline potentiates the effects of levodopa, the adverse reactions of levodopa may be increased and pre-existing dyskinesia exacerbated. 
Budući da razagilin pojačava učinke levodope, nuspojave levodope mogu se povećati i već postojeća diskinezija pogoršati.
Symptoms reported following overdose of Rasagiline ratiopharm included slightly euphoric mood (light form of mania), extremely high blood pressure and serotonin syndrome (see section 4). 
Simptomi zabilježeni nakon predoziranja Razagilin ratiopharmom uključivali su blago euforično raspoloženje (blagi oblik manije), krajnje visok krvni tlak i serotoninski sindrom (vidjeti dio 4).
In mice, increased incidences of combined bronchiolar/alveolar adenoma and/or carcinoma were observed at systemic exposures, 144 - 213 times the expected plasma exposure in humans at 1 mg/day. 
U miševa je opažena povećana incidencija kombiniranih bronhiolarnih/alveolarnih adenoma i/ili karcinoma pri sistemskim ekspozicijama 144-213 puta većim od očekivane plazmatske ekspozicije u ljudi pri dozi od 1 mg/dan.
Concomitant use of rasagiline with other medicinal products 
Istodobna primjena razagilina s drugim lijekovima
The use of Rasagiline ratiopharm together with the antidepressants containing fluoxetine or fluvoxamine should be avoided. 
Istodobnu primjenu Razagilin ratiopharma s antidepresivima koji sadrže fluoksetin ili fluvoksamin potrebno je izbjegavati.
Non-clinical data indicate that rasagiline inhibits prolactin secretion and thus, may inhibit lactation. 
Neklinički podaci pokazuju da razagilin inhibira sekreciju prolaktina i prema tome, može inhibirati laktaciju.
- Involuntary movements (dyskinesia) - Headache 
- nevoljni pokreti (diskinezija) - glavobolja
Fever, Malaise 
Vrućica, Malaksalost
Patients should be cautioned about possible additive effects of sedating medicinal products, alcohol, or other central nervous system depressants (e.g. benzodiazepines, antipsychotics, antidepressants) in combination with rasagiline, or when taking concomitant medications that increase plasma levels of rasagiline (e.g. ciprofloxacin) (see section 4.4). 
Bolesnike treba upozoriti na moguće dodatne učinke lijekova za smirenje, alkohola ili drugih depresora središnjeg živčanog sustava (primjerice benzodiazepina, antipsihotika, antidepresiva) u kombinaciji s razagilinom ili prilikom istodobnog uzimanja lijekova koji povećavaju razine razagilina u plazmi (primjerice ciprofloksacin) (vidjeti dio 4.4).
Co-administration of rasagiline and ciprofloxacin (an inhibitor of CYP1A2) increased the AUC of rasagiline by 83%. 
Istodobna primjena razagilina i ciprofloksacina (inhibitora CYP1A2) je povećala AUC razagilina za 83 %.
Symptoms reported following overdose of rasagiline in doses ranging from 3 mg to 100 mg included hypomania, hypertensive crisis and serotonin syndrome. 
Simptomi prijavljeni nakon predoziranja razagilinom u dozama u rasponu od 3 mg do 100 mg uključivali su hipomaniju, hipertenzivnu krizu i serotoninski sindrom.
Patients being treated with rasagiline and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until they have gained sufficient experience with rasagiline and other dopaminergic medications to gauge whether or not it affects their mental and/or motor performance adversely. 
Bolesnike koji se liječe razagilinom te koji osjećaju somnolenciju i/ili imaju epizode iznenadnog nastupa sna treba obavijestiti da se suzdrže od vožnje ili sudjelovanja u aktivnostima pri kojima narušena pozornost može njih ili druge dovesti u opasnost od ozbiljne ozljede ili smrti (primjerice upravljanje strojevima) sve dok ne steknu dovoljno iskustva s razagilinom i drugim dopaminergičkim lijekovima kako bi mogli prosuditi utječe li lijek negativno na njihove mentalne i/ili motoričke sposobnosti.
Ex vivo and in vitro experiments demonstrate that rasagiline is neither inhibitor nor inducer of major CYP450 enzymes (see section 4.5). 
Ex vivo te in vitro eksperimenti pokazuju da razagilin niti inhibira niti inducira glavne enzime sustava CYP450 (vidjeti dio 4.5).
In patients experiencing somnolence/sudden sleep episodes, rasagiline may have major influence on the ability to drive and use machines. 
U bolesnika koji osjete somnolenciju/epizode iznenadnog nastupa sna, razagilin može značajno utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
In the post-marketing period, cases of elevated blood pressure, including rare serious cases of hypertensive crisis associated with ingestion of unknown amounts of tyramine-rich foods, have been reported in patients taking rasagiline. 
U razdoblju nakon stavljanja lijeka u promet prijavljeni su slučajevi povišenog krvnog tlaka, uključujući i rijetke ozbiljne slučajeve hipertenzivne krize povezane s ingestijom nepoznatih količina hrane bogate tiraminom u bolesnika koji su uzimali razagilin.
Rasagiline ratiopharm may be taken with or without food. 
Razagilin ratiopharm se može uzeti sa ili bez hrane.
Rasagiline ratiopharm may cause drowsiness and may cause you to suddenly fall asleep during day time activities, especially if you are taking other dopaminergic medicinal products (used for the treatment of Parkinson's disease). 
Razagilin ratiopharm može uzrokovati omamljenost i može učiniti da iznenada zaspite tijekom dnevnih aktivnosti, posebice ako uzimate dopaminergičke lijekove (primjenjuju se za liječenje Parkinsonove bolesti).
Rasagiline clinical trials did not allow concomitant use of fluoxetine or fluvoxamine with rasagiline, but the following antidepressants and doses were allowed in the rasagiline trials: amitriptyline ≤ 50 mg/daily, trazodone ≤ 100 mg/daily, citalopram ≤ 20 mg/daily, sertraline ≤ 100 mg/daily, and paroxetine ≤ 30 mg/daily (see section 4.5). 
U kliničkim ispitivanjima razagilina nije bila dozvoljena istodobna upotreba fluoksetina ili fluvoksamina s razagilinom, ali sljedeći antidepresivi i doze bili su dozvoljeni u ispitivanjima razagilina: amitriptilin ≤ 50 mg/dnevno, trazodon ≤ 100 mg/dnevno, citalopram ≤ 20 mg/dnevno, sertralin ≤ 100 mg/dnevno i paroksetin ≤ 30 mg/dnevno (vidjeti dio 4.5).
How to store Rasagiline ratiopharm Contents of the pack and other information 
Kako čuvati Razagilin ratiopharm Sadržaj pakiranja i druge informacije
Non-clinical data indicate that rasagiline has no effect on fertility. 
Neklinički podaci pokazuju da razagilin ne utječe na plodnost.
Concomitant use of rasagiline and levodopa 
Istodobna primjena razagilina i levodope
The difference between the mean change from baseline to week 26/termination (LOCF, Last Observation Carried Forward) was statistically significant (UPDRS, parts I-III: for rasagiline 1 mg compared to placebo -4.2, 95% CI [-5.7, -2.7]; p<0.0001; for rasagiline 2 mg compared to placebo -3.6, 95% CI [-5.0, -2.1]; p<0.0001, UPDRS Motor, part II: for rasagiline 1 mg compared to placebo -2.7, 95% CI [-3.87, -1.55], p<0.0001; for rasagiline 2 mg compared to placebo -1.68, 95% CI [-2.85, -0.51], p=0.0050). 
Last Observation Carried Forward; posljednje provedeno zapažanje preneseno dalje) je bila statistički značajna (UPDRS, dijelovi I-III: za razagilin 1 mg u usporedbi s placebom -4,2, 95 % CI [-5,7, -2,7]; p< 0,0001; za razagilin 2 mg u usporedbi s placebom -3,6, 95 % CI [-5,0, -2,1]; p< 0,0001, UPDRS motorička, dio II: za razagilin 1 mg u usporedbi s placebom2,7, 95 % CI [-3,87, -1,55], p< 0,0001; za razagilin 2 mg u usporedbi s placebom -1,68, 95 % CI [-2,85, -0,51], p=0,0050).
There is no relevant use of Rasagiline ratiopharm in the paediatric population in the indication Parkinson's disease. 
Nema relevantne primjene lijeka Razagilin ratiopharm u pedijatrijskoj populaciji za indikaciju Parkinsonove bolesti.
The robustness of the results for the primary efficacy endpoint, was confirmed in a battery of additional statistical models and was demonstrated in three cohorts (ITT, per protocol and completers). 
Pouzdanost rezultata primarnog ishoda djelotvornosti potvrđena je cijelim skupom dodatnih statističkih modela i pokazana je u tri kohorte (populacija planirana za liječenje (engl. intention to treat, (ITT)), prema protokolu i onim bolesnicima koji su dovršili ispitivanje).
Rasagiline ratiopharm is indicated in adults for the treatment of idiopathic Parkinson's disease as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. 
Razagilin ratiopharm je indiciran u odraslih za liječenje idiopatske Parkinsonove bolesti kao monoterapija (bez levodope) ili kao dodatna terapija (s levodopom) u bolesnika s fluktuacijama prilikom isteka doze.
If you are starting treatment with fluoxetine or fluvoxamine, you should wait at least 14 days after stopping Rasagiline ratiopharm treatment. 
Ako započinjete liječenje fluoksetinom ili fluvoksaminom, morate čekati najmanje 14 dana nakon prekida liječenja Razagilin ratiopharmom.
White to off-white, round, flat, bevelled tablets, debossed with “GIL” and “1” underneath on one side and plain on the other side. 
Bijele do bjelkaste, okrugle, plosnate tablete kosih rubova s utisnutom oznakom «GIL» i «1» ispod toga na jednoj strani, a bez oznake na drugoj strani.
There are no data from the use of rasagiline in pregnant women. 
Nema podataka o primjeni razagilina u trudnica.
In postmarketing period, there was one case of elevated blood pressure in a patient using the ophthalmic vasoconstrictor tetrahydrozoline hydrochloride while taking rasagiline. 
U razdoblju nakon stavljanja lijeka u promet bio je jedan slučaj povišenog krvnog tlaka u bolesnika koji je primijenjivao oftalmički vazokonstriktor tetrahidrozolinklorid tijekom uzimanja razagilina.
Especially tell your doctor if you are taking any of the following medicines: - Certain antidepressants (selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, tricyclic or tetracyclic antidepressants) - The antibiotic ciprofloxacin used against infections - The cough suppressant dextromethorphan - Sympathomimetics such as those present in eye drops, nasal and oral decongestants and cold medicine containing ephedrine or pseudoephedrine 
Posebice obavijestite svog liječnika ako uzimate bilo koji od sljedećih lijekova - određene antidepresive (selektivne inhibitore ponovne pohrane serotonina, selektivne inhibitore ponovne pohrane serotonina i noradrenalina, tricikličke ili tetracikličke antidepresive) - antibiotik ciprofloksacin koji se primjenjuje protiv infekcija - dekstrometorfan koji se primjenjuje protiv kašlja - simpatomimetike poput onih sadržanih u kapima za oči, nazalnim i oralnim dekongestivima i lijekovima za prehladu koji sadrže efedrin ili pseudoefedrin.
Do not take Rasagiline ratiopharm - If you are allergic to rasagiline or any of the other ingredients of this medicine (listed in section 6). 
- ako ste alergični na razagilin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
In a dose escalation study in patients on chronic levodopa therapy treated with 10 mg/day of rasagiline, there were reports of cardiovascular adverse reactions (including hypertension and postural hypotension) which resolved following treatment discontinuation. 
U ispitivanju postupnog povećavanja doze kod bolesnika na kroničnoj terapiji levodopom liječenih s 10 mg/dan razagilina prijavljene su kardiovaskularne nuspojave (uključujući hipertenziju i posturalnu hipotenziju) koje su se povukle po prestanku liječenja.
Rasagiline is contraindicated along with other MAO inhibitors (including medicinal and natural products without prescription e.g. St. John's Wort) as there may be a risk of non-selective MAO inhibition that may lead to hypertensive crises (see section 4.3). 
Razagilin je kontraindiciran zajedno s drugim MAO inhibitorima (uključujući lijekove i prirodne preparate bez recepta npr. gospinu travu) jer je moguć rizik od neselektivne MAO inhibicije, koja može dovesti do hipertenzivnih kriza (vidjeti dio 4.3).
The safety and efficacy of Rasagiline ratiopharm in children and adolescents have not been established. 
Sigurnost i djelotvornost lijeka Razagilin ratiopharm u djece i adolescenata nisu ustanovljene.
In vitro studies showed that rasagiline at a concentration of 1 µg/ml (equivalent to a level that is 160 times the average Cmax ~ 5.9-8.5 ng/ml in Parkinson's disease patients after 1 mg rasagiline multiple dosing), did not inhibit cytochrome P450 isoenzymes, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP4A. 
Ispitivanja in vitro su pokazala da razagilin u koncentraciji od 1 µg/ml (istovjetno razini koja je 160 puta veća od prosječne Cmax ~ 5,9-8,5 ng/ml u bolesnika s Parkinsonovom bolešću nakon višekratnog doziranja 1 mg razagilina) nije inhibirao izoenzime citokroma P450, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2El, CYP3A4 i CYP4A.
For concomitant use of rasagiline with selective serotonin reuptake inhibitors (SSRIs)/selective serotoninnorepinephrine reuptake inhibitors (SNRIs) in clinical trials, see section 4.8. 
Za istodobnu primjenu razagilina sa selektivnim inhibitorima ponovne pohrane serotonina (engl. selective serotonin reuptake inhibitors (SSRI))/selektivnim inhibitorima ponovne pohrane serotonina i noradrenalina (engl. selective serotonin norepinephrine reuptake inhibitors (SNRI)) u kliničkim ispitivanjima, vidjeti dio 4.8.
The tablets are available in blister packs of 7, 10, 28, 30, 100 and 112 tablets, in perforated unit dose blister packs of 10 x 1, 30 x 1 and 100 x 1 tablets or in a bottle containing 30 tablets. 
Tablete su dostupne u blister pakiranjima od 7, 10, 28, 30, 100 i 112 tableta, u perforiranim blisterima s jediničnim dozama u pakiranjima od 10 x 1, 30 x 1 i 100 x 1 tableta ili u bočici koja sadrži 30 tableta.
Incidence of skin melanoma in placebo-controlled clinical studies was 2/380 (0.5%) in rasagiline 1 mg as adjacent to levodopa therapy group vs. 1/388 (0.3%) incidence in placebo group. 
Incidencija melanoma kože u placebom kontroliranim kliničkim ispitivanjima iznosila je 2/380 (0,5 %) u skupini koja je primala razagilin u dozi od 1 mg kao dodatnu terapiju levodopi naspram incidencije od 1/388 (0,3 %) u skupini koja je primala placebo.
If you have experienced somnolence and/or episodes of sudden sleep onset before, or while taking Rasagiline ratiopharm do not drive or operate machinery (see section 2). 
Ako ste osjetili izrazitu pospanost i/ili epizode iznenadnog nastupa sna prije ili za vrijeme uzimanja lijeka Razagilin ratiopharm, nemojte upravljati vozilima ili strojevima (pogledajte dio 2).
In subjects with moderate hepatic impairment, AUC and Cmax were increased by 568% and 83%, respectively (see section 4.4). 
U osoba s umjerenim oštećenjem jetre, AUC se povećava za 568 %, a Cmax za 83 % (vidjeti dio 4.4).
Cases of patients, treated with rasagiline and other dopaminergic medicinal products, falling asleep while engaged in activities of daily living have been reported. 
Zabilježeni su slučajevi bolesnika liječenih razagilinom i drugim dopaminergicima koji su zaspali dok su obavljali svakodnevne aktivnosti.
The following were reported during post-marketing exposure with unknown frequency: compulsions, compulsive shopping, dermatillomania, dopamine dysregulation syndrome, impulse-control disorder, impulsive behaviour, kleptomania, theft, obsessive thoughts, obsessive-compulsive disorder, stereotypy, gambling, pathological gambling, libido increased, hypersexuality, psychosexual disorder, sexually inappropriate behaviour. 
Sljedeći su slučajevi prijavljeni tijekom izloženosti nakon stavljanja lijeka u promet s nepoznatom učestalošću: kompulzije, kompulzivno kupovanje, dermatilomanija, sindrom disregulacije dopamina, poremećaj kontrole impulsa, impulzivno ponašanje, kleptomanija, krađa, opsesivne misli, opsesivnokompulzivni poremećaj, stereotipija, kockanje, patološko kockanje, povećani libido, hiperseksualnost, psihoseksualni poremećaj, neprimjereno seksualno ponašanje.
If you are starting treatment with Rasagiline ratiopharm, you should wait at least 5 weeks after stopping fluoxetine treatment. 
Ako započinjete liječenje Razagilin ratiopharmom, morate čekati najmanje 5 tjedana nakon prekida liječenja fluoksetinom.
Agents that affect CYP1A2 activity 
Lijekovi koji utječu na aktivnost CYP1A2
Rasagiline ratiopharm contains the active substance rasagiline and it is used for the treatment of Parkinson's disease in adults. 
Razagilin ratiopharm sadrži djelatnu tvar razagilin te se primjenjuje za liječenje Parkinsonove bolesti u odraslih.
No special precautions are required in patients with renal impairment. 
Nisu potrebne posebne mjere opreza u bolesnika s oštećenjem bubrega.
What you need to know before you take Rasagiline ratiopharm 
Što morate znati prije nego počnete uzimati Razagilin ratiopharm
Aluminium/aluminium perforated unit dose blister packs of 10 x 1, 30 x 1 and 100 x 1 tablets. 
Aluminij/aluminij perforirani blister s jediničnim dozama u pakiranju od 10 x 1, 30 x 1 i 100 x 1 tableta.
No human data on the effect of rasagiline on fertility are available. 
Nema dostupnih podataka o učinku razagilina na plodnost.
Concomitant administration of rasagiline and entacapone increased rasagiline oral clearance by 28%. 
Istodobna primjena razagilina i entakapona povećava oralni klirens razagilina za 28 %.
Do not take the following medicines while taking Rasagiline ratiopharm: - Monoamine oxidase (MAO) inhibitors (e.g. for treatment of depression or Parkinson's disease, or used for any other indication), including medicinal and natural products without prescription e.g. 
Nemojte uzimati sljedeće lijekove dok uzimate Razagilin ratiopharm: - inhibitore monoaminooksidaze (MAO) (npr. za liječenje depresije ili Parkinsonove bolesti ili za bilo koju drugu indikaciju), uključujući lijekove i prirodne preparate bez recepta npr. gospinu travu - petidin (snažan lijek protiv boli).
The mean total daily decrease in the OFF time was similar in the entacapone group (-0.80h, 95% CI [-1.20, -0.41], p<0.0001) to that observed in the rasagiline 1 mg group. 
Srednje ukupno dnevno smanjenje u OFF vremenu u entakapon skupini (-0,80 h, 95 % CI [-1,20, -0,41], p< 0,0001) bilo je slično onom opaženom u razagilin 1 mg skupini.
- The other ingredients are mannitol, colloidal anhydrous silica, maize starch, pregelatinised maize starch, stearic acid, talc. 
- Drugi sastojci su manitol, koloidni, bezvodni silicijev dioksid, kukuruzni škrob, prethodno geliran kukuruzni škrob, stearatna kiselina, talk.
Rasagiline is contraindicated in patients with severe hepatic impairment (see section 4.3). 
Primjena razagilina je kontraindicirana u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
What Rasagiline ratiopharm is and what it is used for 
Što je Razagilin ratiopharm i za što se koristi
What Rasagiline ratiopharm looks like and contents of the pack Rasagiline ratiopharm tablets are presented as white to off-white, round, flat, bevelled tablets, debossed with “GIL” and “1” underneath on one side and plain on the other side. 
Kako Razagilin ratiopharm izgleda i sadržaj pakiranja Razagilin ratiopharm tablete su bijele do bjelkaste, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom „GIL” i „1” ispod toga na jednoj strani, i bez oznake na drugoj strani.